Skip to main content
. Author manuscript; available in PMC: 2024 Sep 26.
Published in final edited form as: J Infect. 2022 Mar 1;84(5):658–667. doi: 10.1016/j.jinf.2022.02.032

Fig. 5.

Fig. 5

Antibody responses to PorA P1.7–2,4 adenoviral vectors with OMV boosting. Groups of 8 BALB/c mice were immunised with 109 IU of adenoviral vectors Ad-P1.7–2,4, Ad-FliC-VR1.4-C or 5 μg of OMVs from strain NZ98/254 and all boosted with OMVs at week 8, Vaccination time-points are marked with arrows. ELISAs were performed against recombinant PorA rP1.7–2,4. Kruskal Wallis with Dunn’s multiple comparison tests were used to perform comparisons between week 6 vs. week 14 or week 20 for Ad-FliC-VR1.4-C boosted with OMV (asterisks) or OMV boosted with OMV (crosses) ∗ or + = P ≤ 0.05, ++ = P ≤ 0.01 and ∗∗∗ = P ≤ 0.001 .